Gene editing startup Editas Medicine of Cambridge has appointed former Avila Therapeutics chief executive Katrine S. Bosley as its new CEO.
The company launched in November with $43 million from Flagship Ventures, Polaris, and Third Rock Ventures. Founders of the company include Harvard’s George Church and MIT’s Feng Zhang.
Bosley takes over for Kevin Bitterman, a partner at Polaris Partners, who had been serving as interim chief executive.
Editas has developed a way to potentially reengineer any gene in the human genome, a development that holds the promise of treating any disease with a genetic underpinning, Bitterman said recently.
Bosley had recently been a Broad Institute entrepreneur-in-residence. Before serving as chief executive of Avila — which Celgene acquired in 2012 — she had held positions at Adnexus Therapeutics, Biogen Idec, Highland Capital Partners, and Alkermes.
At Editas, Bosley will bring her two decades of experience to bear in “advancing genome editing as a new therapeutic class,” Bitterman said in a news release.
Kyle Alspach has worked in journalism in Massachusetts since 2005 and was one of the original staff writers at BetaBoston.
Follow Kyle on Twitter